Government of India and Pharma Industry Jointly Form the India Responsible Healthcare Trust
The India Brand Equity Foundation (IBEF), annouces on behalf of the Government of India and the major pharmaceutical industry organisations have come together to form the India – Responsible Healthcare Trust. This significant development has been designed to power the Brand India Pharma campaign. A one of its kind public–private partnership, the formation of the Trust represents the commitment to both drive and safeguard the interests of the Indian pharma industry.
The Trust chaired by the Commerce Secretary comprises key stakeholders, namely, the Indian Pharmaceutical Alliance (IPA), Indian Drug Manufacturers’ Association (IDMA), Bulk Drug Manufacturers Association (BDMA), Association of Biotechnology Led Enterprises (ABLE), Pharmaceutical Export Promotion Council of India (Pharmexcil) and India Brand Equity Foundation (IBEF). The Trust aims to combine both financial and non-financial resources towards a common agenda.
The Trust aims to create better awareness and develop an informed perspective about Brand India Pharma in both the domestic and global markets.
“The India – Responsible Healthcare Trust will spearhead the Brand India Pharma initiative through the second phase. The industry-government partnership is an important milestone in the campaign,” said Mr Rajeev Kher, Commerce Secretary, Government of India.
The Brand India Pharma campaign was launched under the aegis of the Department of Commerce at CPHI Japan in March 2012. The Brand India Pharma showcase has made its presence felt at prestigious events like CPHI Worldwide consistently over the past two years. The Department of Commerce along with IBEF and Pharmexcil has invested huge resources with measurable and impacting results in the first phase of the Brand India Pharma campaign.
The India – Responsible Healthcare Trust is expected to take the Brand India Pharma campaign to the next level. The primary objective of this Trust will be to position India as a Responsible Healthcare provider.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance